![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRRC49 |
Gene summary for LRRC49 |
![]() |
Gene information | Species | Human | Gene symbol | LRRC49 | Gene ID | 54839 |
Gene name | leucine rich repeat containing 49 | |
Gene Alias | PGs4 | |
Cytomap | 15q23 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | B7Z7G0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54839 | LRRC49 | HTA12-15-2 | Human | Pancreas | PDAC | 4.41e-04 | 3.35e-01 | 0.2315 |
54839 | LRRC49 | HTA12-25-1 | Human | Pancreas | PDAC | 3.68e-04 | 3.89e-01 | 0.313 |
54839 | LRRC49 | HTA12-26-1 | Human | Pancreas | PDAC | 1.03e-14 | 6.03e-01 | 0.3728 |
54839 | LRRC49 | HTA12-29-1 | Human | Pancreas | PDAC | 4.01e-22 | 5.35e-01 | 0.3722 |
54839 | LRRC49 | HTA12-32-1 | Human | Pancreas | PDAC | 4.65e-02 | 6.42e-01 | 0.3624 |
54839 | LRRC49 | 048752_1579-all-cells | Human | Prostate | BPH | 2.02e-31 | 6.73e-01 | 0.1008 |
54839 | LRRC49 | 052095_1628-all-cells | Human | Prostate | BPH | 8.59e-10 | 3.33e-01 | 0.1032 |
54839 | LRRC49 | 052097_1595-all-cells | Human | Prostate | BPH | 9.40e-14 | 5.44e-01 | 0.0972 |
54839 | LRRC49 | 052099_1652-all-cells | Human | Prostate | BPH | 4.86e-09 | 4.47e-01 | 0.1038 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRC49 | SNV | Missense_Mutation | novel | c.1793N>A | p.Ser598Asn | p.S598N | Q8IUZ0 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRRC49 | SNV | Missense_Mutation | rs763641412 | c.724N>A | p.Val242Met | p.V242M | Q8IUZ0 | protein_coding | tolerated(0.08) | possibly_damaging(0.74) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRRC49 | SNV | Missense_Mutation | novel | c.276G>T | p.Glu92Asp | p.E92D | Q8IUZ0 | protein_coding | tolerated(0.11) | possibly_damaging(0.508) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
LRRC49 | SNV | Missense_Mutation | novel | c.1114G>T | p.Asp372Tyr | p.D372Y | Q8IUZ0 | protein_coding | tolerated(0.06) | benign(0.087) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
LRRC49 | SNV | Missense_Mutation | novel | c.1789N>A | p.Asp597Asn | p.D597N | Q8IUZ0 | protein_coding | tolerated(0.05) | benign(0.015) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LRRC49 | SNV | Missense_Mutation | c.1890N>T | p.Lys630Asn | p.K630N | Q8IUZ0 | protein_coding | tolerated(0.18) | benign(0.059) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
LRRC49 | SNV | Missense_Mutation | novel | c.1938N>C | p.Glu646Asp | p.E646D | Q8IUZ0 | protein_coding | tolerated(1) | benign(0) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LRRC49 | SNV | Missense_Mutation | novel | c.1288N>T | p.Ala430Ser | p.A430S | Q8IUZ0 | protein_coding | tolerated(0.14) | possibly_damaging(0.462) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
LRRC49 | SNV | Missense_Mutation | c.1109N>C | p.Arg370Thr | p.R370T | Q8IUZ0 | protein_coding | tolerated(0.75) | benign(0) | TCGA-BG-A18A-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRRC49 | SNV | Missense_Mutation | novel | c.1828N>G | p.Thr610Ala | p.T610A | Q8IUZ0 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |